FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Milton Packer

Research Profile

Disorders

Physiology

Chemicals & Drugs

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Scott D Solomon; Madoka Takeuchi; Adriaan Voors; Michael Zile; Toni Bransford; Jianjian Gong; Elisabeth Kraigher-Krainer; Martin Lefkowitz; John J V McMurray; Milton Packer; Burkert Pieske; Amil Shah; Victor Shi
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Amit G Singal; William M Lee; Milton Packer; Celette S Skinner; Adam Yopp; Jasmin A Tiro
Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review.
Congcong He; Joseph A Hill; Stanley Korsmeyer; Zhenyi An; Rhonda Bassel-Duby; Michael C Bassik; Jill Fisher; Christopher Gilpin; Joy Loh; Herman I May; Viviana Moresi; Milton Packer; Philipp E Scherer; Kai Sun; Qihua Sun; Herbert W Virgin; Yongjie Wei; Guanghua Xiao; Zhongju Zou; Beth Levine
Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Milton Packer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Scott D Solomon; Madoka Takeuchi; Adriaan Voors; Michael Zile; Toni Bransford; Jianjian Gong; Elisabeth Kraigher-Krainer; Martin Lefkowitz; John J V McMurray; Milton Packer; Burkert Pieske; Amil Shah; Victor Shi
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Lancet 2012;380(9851):1387-95.
2012: Amit G Singal; William M Lee; Milton Packer; Celette S Skinner; Adam Yopp; Jasmin A Tiro
Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review.
Journal of general internal medicine 2012;27(7):861-7.
2012: Congcong He; Joseph A Hill; Stanley Korsmeyer; Zhenyi An; Rhonda Bassel-Duby; Michael C Bassik; Jill Fisher; Christopher Gilpin; Joy Loh; Herman I May; Viviana Moresi; Milton Packer; Philipp E Scherer; Kai Sun; Qihua Sun; Herbert W Virgin; Yongjie Wei; Guanghua Xiao; Zhongju Zou; Beth Levine
Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis.
Nature 2012;481(7382):511-5.
2011: Milton Packer
Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease.
Circulation. Heart failure 2011;4(5):538-40.
2007: Alexandre Mebazaa; Markku S Nieminen; Milton Packer; Alain Cohen-Solal; Franz X Kleber; Stuart J Pocock; Roopal Thakkar; Robert J Padley; Pentti Põder; Matti Kivikko
Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
JAMA : the journal of the American Medical Association 2007;297(17):1883-91.
2007: Camille G Frazier; Karen P Alexander; L Kristin Newby; Susan Anderson; Erik Iverson; Milton Packer; Jay Cohn; Sidney Goldstein; Pamela S Douglas
Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials.
Journal of the American College of Cardiology 2007;49(13):1450-8.
2007: S William Tam; Michael L Sabolinski; Manuel Worcel; Milton Packer; Jay N Cohn
Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
Clinical pharmacokinetics 2007;46(10):885-95.
2006: Milton Packer
Controlled-release carvedilol: a concluding perspective.
The American journal of cardiology 2006;98(7A):67L-69L.
2006: Milton Packer; Mary Ann Lukas; David M Tenero; Charlotte A Baidoo; Barry H Greenberg
Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
The American journal of cardiology 2006;98(7A):39L-45L.
2006: Milton Packer; William T Abraham; Mandeep Mehra; Clyde W Yancy; Christine E Lawless; Judith E Mitchell; Frank W Smart; Rachel Bijou; Christopher M O'Connor; Barrie Massie; Ileana Pina; Barry H Greenberg; James B Young; Daniel P Fishbein; Paul J Hauptman; Robert Bourge; John E Strobeck; Srinvivas Murali; Douglas Schocken; John R Teerlink; Wayne C Levy; Robin J Trupp; Marc A Silver
Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure.
Journal of the American College of Cardiology 2006;47(11):2245-52.
2006: Wayne C Levy; Dariush Mozaffarian; David T Linker; Santosh C Sutradhar; Stefan D Anker; Anne B Cropp; Inder Anand; Aldo Maggioni; Paul Burton; Mark D Sullivan; Bertram Pitt; Philip A Poole-Wilson; Douglas L Mann; Milton Packer
The Seattle Heart Failure Model: prediction of survival in heart failure.
Circulation 2006;113(11):1424-33.
2006: Henry Krum; Paul Mohacsi; Hugo A Katus; Michal Tendera; Jean-Lucien Rouleau; Michael B Fowler; Andrew J Coats; Ellen B Roecker; Milton Packer
Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.
American heart journal 2006;151(1):55-61.
2005: Henry Krum; Steven Joseph Haas; Eric Eichhorn; Jalal K Ghali; Edward Gilbert; Philippe Lechat; Milton Packer; Ellen B Roecker; Patricia Verkenne; Hans Wedel; John Wikstrand
Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors.
European heart journal 2005;26(20):2154-8.
2005: Sophie Pattingre; Amina Tassa; Xueping Qu; Rita Garuti; Xiao Huan Liang; Noboru Mizushima; Milton Packer; Michael D Schneider; Beth Levine
Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy.
Cell 2005;122(6):927-39.
2005: Scott D Solomon; Hicham Skali; Mikhail Bourgoun; James Fang; Jalal K Ghali; Michel Martelet; Dariusz Wojciechowski; Baiba Ansmite; Janis Skards; Toivo Laks; David Henry; Milton Packer; Marc A Pfeffer
Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
American heart journal 2005;150(2):257-62.
2005: Simon Stewart; john mcmurray; Ansgar Hebborn; Andrew J S Coats; Milton Packer
Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom.
International journal of cardiology 2005;100(1):143-9.
2005: Matthew Maurer; Donald L King; Lyna El-Khoury Rumbarger; Milton Packer; Daniel Burkhoff
Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms.
Journal of cardiac failure 2005;11(3):177-87.
2005: Milton Packer; John McMurray; Barrie Massie; Abraham Caspi; Vincent Charlon; Alain Cohen-Solal; Wolfgang Kiowski; William J Kostuk; Henry Krum; Barry Levine; Paolo Rizzon; Jordi Soler; Karl Swedberg; Susan Anderson; David L DeMets
Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study.
Journal of cardiac failure 2005;11(1):12-20.
2005: Eric Stanton; Mark S Hansen; Michael J Sole; Yehia Gawad; Milton Packer; Bertram Pitt; Karl Swedberg; Jean-Lucien Rouleau
Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure.
The Canadian journal of cardiology 2005;21(1):39-43.
2004: Mariya P Tokmakova; Hicham Skali; Satish Kenchaiah; Eugene Braunwald; Jean-Lucien Rouleau; Milton Packer; Glenn M Chertow; Lemuel A Moyé; Marc A Pfeffer; Scott D Solomon
Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.
Circulation 2004;110(24):3667-73.
2004: Milton Packer
Milton Packer, MD, Director, Center for Biostatistics and Clinical Science at UT Southwestern.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2004;52(7):421-4.
2004: Franz Hartmann; Milton Packer; Andrew J S Coats; Michael B Fowler; Henry Krum; Paul Mohacsi; Jean-Lucien Rouleau; Michal Tendera; Alain Castaigne; Stefan D Anker; Ildiko Amann-Zalan; Silke Hoersch; Hugo A Katus
Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.
Circulation 2004;110(13):1780-6.
2004: Matthew Maurer; Milton Packer; Daniel Burkhoff
Diastolic heart failure.
The New England journal of medicine 2004;351(11):1143-5; author reply 1143-5.
2004: Sumit R Majumdar; Finlay A McAlister; Marilyn Cree; Wei-Ching Chang; Milton Packer; Paul W Armstrong
Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study.
Clinical therapeutics 2004;26(5):694-703.
2004: Alan H B Wu; Milton Packer; Andrew Smith; Rachel Bijou; Daniel Fink; Johannes Mair; Lars Wallentin; Nina Johnston; Carolyn S Feldcamp; Doris M Haverstick; Charaf E Ahnadi; Andrew Grant; Normand Despres; Barry I Bluestein; Farooq Ghani
Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study.
Clinical chemistry 2004;50(5):867-73.
2004: Jean-Lucien Rouleau; Ellen B Roecker; Michal Tendera; Paul Mohacsi; Henry Krum; Hugo A Katus; Michael B Fowler; Andrew J S Coats; Alain Castaigne; Armin Scherhag; Terry L Holcslaw; Milton Packer
Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study.
Journal of the American College of Cardiology 2004;43(8):1423-9.
2004: Douglas L Mann; john mcmurray; Milton Packer; Karl Swedberg; Jeffrey S Borer; Wilson S Colucci; Jacques Djian; Helmut Drexler; Arthur M Feldman; Lars Kober; Henry Krum; Peter Liu; Markku Nieminen; Luigi Tavazzi; Dirk Jan van Veldhuisen; Anders Waldenstrom; Marshelle Warren; Arne Westheim; Faiez Zannad; Thomas Fleming
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).
Circulation 2004;109(13):1594-602.
2004: Barrie Massie; William F Krol; Susan E Ammon; Paul W Armstrong; John G F Cleland; Joseph F Collins; Michael Ezekowitz; Syed M Jafri; Christopher M O'Connor; Milton Packer; Kevin Schulman; Koon Teo; Stuart Warren
The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics.
Journal of cardiac failure 2004;10(2):101-12.
2004: Marvin A Konstam; JoAnn Lindenfeld; Ileana Pina; Milton Packer; Ronald M Lazar; Lynne Warner-Stevenson
Key issues in trial design for ventricular assist devices: a position statement of the Heart Failure Society of America.
Journal of cardiac failure 2004;10(2):91-100.
2004: Franz Hartmann; Milton Packer; Andrew J S Coats; Michael B Fowler; Henry Krum; Paul Mohacsi; Jean-Lucien Rouleau; Michal Tendera; Alain Castaigne; Jürgen Trawinski; Ildiko Amann-Zalan; Silke Hoersch; Hugo A Katus
NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy.
European journal of heart failure 2004;6(3):343-50.
2004: David L DeMets; Robert M Califf; Dennis Dixon; Susan S Ellenberg; Thomas Fleming; Peter Held; Desmond Julian; Richard S. Kaplan; Robert Levine; James D Neaton; Milton Packer; Stuart Pocock; Frank Rockhold; Belinda Seto; Jay Siegel; Steven M Snapinn; David Stump; Robert Temple; Richard Whitley
Issues in regulatory guidelines for data monitoring committees.
Clinical trials (London, England) 2004;1(2):162-9.
2003: Milton Packer
Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure?
Circulation 2003;108(24):2950-3.
2003: Milton Packer
Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial.
Journal of cardiac failure 2003;9(6):429-43.
2003: Eugene S Chung; Milton Packer; Kim Hung Lo; Adedigbo A Fasanmade; James T Willerson
Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.
Circulation 2003;107(25):3133-40.
2003: Marvin A Konstam; Ileana Pina; JoAnn Lindenfeld; Milton Packer
A device is not a drug.
Journal of cardiac failure 2003;9(3):155-7.
2003: Jean-Lucien Rouleau; Bertram Pitt; N S Dhalla; K S Dhalla; Karl Swedberg; Mark S Hansen; Eric Stanton; N Lapointe; Milton Packer
Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure.
American heart journal 2003;145(5):926-32.
2003: Henry Krum; Ellen B Roecker; Paul Mohacsi; Jean-Lucien Rouleau; Michal Tendera; Andrew J S Coats; Hugo A Katus; Michael B Fowler; Milton Packer
Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study.
JAMA : the journal of the American Medical Association 2003;289(6):712-8.
2003: Daniel Burkhoff; Matthew Maurer; Milton Packer
Heart failure with a normal ejection fraction: is it really a disorder of diastolic function?
Circulation 2003;107(5):656-8.
2003: Timothy J Vittorio; Chim C Lang; Stuart D Katz; Milton Packer; Donna M Mancini; Ulrich P Jorde
Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockers.
Circulation 2003;107(2):290-3.
2002: Mark S Hansen; Eric Stanton; Yehia Gawad; Milton Packer; Bertram Pitt; Karl Swedberg; Jean-Lucien Rouleau
Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan.
The American journal of cardiology 2002;90(9):969-73.
2002: Milton Packer; Michael B Fowler; Ellen B Roecker; Andrew J S Coats; Hugo A Katus; Henry Krum; Paul Mohacsi; Jean-Lucien Rouleau; Michal Tendera; Christoph Staiger; Terry L Holcslaw; Ildiko Amann-Zalan; David L DeMets
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.
Circulation 2002;106(17):2194-9.
2002: Milton Packer; Robert M Califf; Marvin A Konstam; Henry Krum; John J McMurray; Jean-Lucien Rouleau; Karl Swedberg
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
Circulation 2002;106(8):920-6.
2002: Milton Packer
The impossible task of developing a new treatment for heart failure.
Journal of cardiac failure 2002;8(4):193-6.
2002: Gerald W Neuberg; Alan B Miller; Christopher M O'Connor; Robert N Belkin; Peter E Carson; Anne B Cropp; David J Frid; Regina G Nye; Milton L Pressler; John H Wertheimer; Milton Packer
Diuretic resistance predicts mortality in patients with advanced heart failure.
American heart journal 2002;144(1):31-8.
2002: William T Abraham; Westby G Fisher; Andrew L Smith; David B DeLurgio; Angel R Leon; Evan Loh; Dusan Z Kocovic; Milton Packer; Alfredo L Clavell; David L Hayes; Myrvin Ellestad; Robin J Trupp; Jackie Underwood; Faith Pickering; Cindy Truex; Peggy McAtee; John Messenger
Cardiac resynchronization in chronic heart failure.
The New England journal of medicine 2002;346(24):1845-53.
2002: Mario C Deng; Jacqueline M A Smits; Milton Packer
Selecting patients for heart transplantation: which patients are too well for transplant?
Current opinion in cardiology 2002;17(2):137-44.
2002: Sharon Ann Hunt; David W Baker; Marshall H Chin; Michael P Cinquegrani; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Sidney Goldstein; Gabriel Gregoratos; Mariell Jessup; R Joseph Noble; Milton Packer; Marc A Silver; Lynne Warner Stevenson; Raymond J Gibbons; Elliott M Antman; Joseph S Alpert; David P Faxon; Valentin Fuster; Gabriel Gregoratos; Alice K Jacobs; Loren F Hiratzka; Richard O Russell; Sidney C Smith
ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2002;21(2):189-203.
2001: Sharon Ann Hunt; D W Baker; Marshall H Chin; Michael P Cinquegrani; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Sidney Goldstein; Gabriel Gregoratos; Mariell Jessup; R Joseph Noble; Milton Packer; Marc A Silver; Lynne Warner Stevenson; R J Gibbons; Elliott M Antman; J S Alpert; David P Faxon; Valentin Fuster; G Gregoratos; Alice K Jacobs; Loren F Hiratzka; Richard O Russell; Sidney C Smith
ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America.
Circulation 2001;104(24):2996-3007.
2001: Sharon Ann Hunt; D W Baker; M H Chin; Michael P Cinquegrani; Arthur M Feldman; G S Francis; Theodore G Ganiats; Sidney Goldstein; Gabriel Gregoratos; Mariell Jessup; R Joseph Noble; Milton Packer; M A Silver; Lynne Warner Stevenson; R J Gibbons; Elliott M Antman; J S Alpert; David P Faxon; Valentin Fuster; Alice K Jacobs; Loren F Hiratzka; Richard O Russell; Sidney C Smith
ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure).
Journal of the American College of Cardiology 2001;38(7):2101-13.
2001: John G F Cleland; K Thygesen; B F Uretsky; P Armstrong; J D Horowitz; Barrie Massie; Milton Packer; P A Poole-Wilson; L Rydén
Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study.
European heart journal 2001;22(17):1601-12.
2001: Milton Packer
Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure.
Journal of cardiac failure 2001;7(2):176-82.
2001: Milton Packer; G V Antonopoulos; J A Berlin; Jesse Chittams; Marvin A Konstam; J E Udelson
Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis.
American heart journal 2001;141(6):899-907.
2001: Milton Packer; Andrew J S Coats; Michael B Fowler; Hugo A Katus; Henry Krum; Paul Mohacsi; Jean-Lucien Rouleau; Michal Tendera; Alain Castaigne; Ellen B Roecker; M K Schultz; David L DeMets
Effect of carvedilol on survival in severe chronic heart failure.
The New England journal of medicine 2001;344(22):1651-8.
2001: Milton Packer
Current role of beta-adrenergic blockers in the management of chronic heart failure.
The American journal of medicine 2001;110 Suppl 7A():81S-94S.
2001: Clyde W Yancy; Michael B Fowler; WS Colucci; Edward M Gilbert; Michael R Bristow; Jay N Cohn; Mary Ann Lukas; ST Young; Milton Packer
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.
The New England journal of medicine 2001;344(18):1358-65.
2001: Michael B Fowler; Montserrat Vera-Llonch; Gerry Oster; Michael R Bristow; Jay N Cohn; WS Colucci; Edward M Gilbert; Mary Ann Lukas; M J Lacey; RE Richner; ST Young; Milton Packer
Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group.
Journal of the American College of Cardiology 2001;37(6):1692-9.
2001: Barrie Massie; PW Armstrong; John G F Cleland; JD Horowitz; Milton Packer; PA Poole-Wilson; L Rydén
Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival.
Archives of internal medicine 2001;161(2):165-71.
2000: L Rydén; P W Armstrong; John G F Cleland; J D Horowitz; Barrie Massie; Milton Packer; P A Poole-Wilson
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial.
European heart journal 2000;21(23):1967-78.
2000: Barry F Uretsky; K Thygesen; PW Armstrong; John G F Cleland; JD Horowitz; Barrie Massie; Milton Packer; PA Poole-Wilson; L Ryden
Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial.
Circulation 2000;102(6):611-6.
2000: P A Carson; Christopher M O'Connor; Alan B Miller; S Anderson; Robert N Belkin; Gerald W Neuberg; John H Wertheimer; David J Frid; Anne B Cropp; Milton Packer
Circadian rhythm and sudden death in heart failure: results from Prospective Randomized Amlodipine Survival Trial.
Journal of the American College of Cardiology 2000;36(2):541-6.
2000: Milton Packer
Dispelling the myth: incorporating beta-blockers into practice guidelines.
The American journal of managed care 2000;6(6 Suppl):S313-6.
2000: G W Moe; J L Rouleau; L Charbonneau; G Proulx; J Malcolm O Arnold; C Hall; J de Champlain; A Barr; P Sirois; Milton Packer
Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan.
American heart journal 2000;139(4):587-95.
2000: Milton Packer
Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure.
American heart journal 2000;139(4):S202-6.
2000: James E Udelson; C A DeAbate; M Berk; G Neuberg; Milton Packer; N K Vijay; J Gorwitt; W B Smith; M L Kukin; T LeJemtel; T Barry Levine; Marvin A Konstam
Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction.
American heart journal 2000;139(3):503-10.
2000: J R Teerlink; M Jalaluddin; S Anderson; M L Kukin; E J Eichhorn; G Francis; Milton Packer; Barrie Massie
Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators.
Circulation 2000;101(1):40-6.
1999: Milton Packer; P A Poole-Wilson; P W Armstrong; John G F Cleland; J D Horowitz; Barrie Massie; L Rydén; K Thygesen; B F Uretsky
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.
Circulation 1999;100(23):2312-8.
1999: Milton Packer; Alan B Miller
Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failure.
The American journal of cardiology 1999;84(4A):1L-2L.
1999: Milton Packer
Implications of the ATLAS study for clinical practice.
International journal of clinical practice. Supplement 1999;100():21-3.
1999: John G F Cleland; P Armstrong; J D Horowitz; Barrie Massie; Milton Packer; P A Poole-Wilson; L Rydén
Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study.
European journal of heart failure 1999;1(1):73-9.
1999: John G F Cleland; Barrie Massie; Milton Packer
Sudden death in heart failure: vascular or electrical?
European journal of heart failure 1999;1(1):41-5.
1999: Eric A Rose; Alan J Moskowitz; Milton Packer; JA Sollano; DL Williams; Anita R Tierney; Daniel F Heitjan; P Meier; Deborah D Ascheim; Ronald G Levitan; Alan D Weinberg; Lynne Warner Stevenson; Peter A Shapiro; Ronald M Lazar; John T Watson; Daniel Goldstein; Annetine Gelijns
The REMATCH trial: rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure.
The Annals of thoracic surgery 1999;67(3):723-30.
1998: Philippe Lechat; Milton Packer; S Chalon; M Cucherat; T Arab; J P Boissel
Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials.
Circulation 1998;98(12):1184-91.
1998: Milton Packer
Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice.
Progress in cardiovascular diseases 1998;41(1 Suppl 1):39-52.
1998: Barrie Massie; John G F Cleland; PW Armstrong; JD Horowitz; Milton Packer; PA Poole-Wilson; L Ryden; R Lars
Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators.
Journal of cardiac failure 1998;4(1):3-8.
1998: Kirkwood F Adams; Mihai Gheorghiade; Barry F Uretsky; J B Young; J Herbert Patterson; L Tomasko; Milton Packer
Clinical predictors of worsening heart failure during withdrawal from digoxin therapy.
American heart journal 1998;135(3):389-97.
1998: Milton Packer
Do beta-blockers prolong survival in chronic heart failure? A review of the experimental and clinical evidence.
European heart journal 1998;19 Suppl B():B40-6.
1998: Milton Packer
Beta-blockade in heart failure. Basic concepts and clinical results.
American journal of hypertension 1998;11(1 Pt 2):23S-37S.
1997: Milton Packer
Effects of beta-adrenergic blockade on survival of patients with chronic heart failure.
The American journal of cardiology 1997;80(11A):46L-54L.
1997: Jack Wang; Geng-Hua Yi; M Knecht; B L Cai; S Poposkis; Milton Packer; Daniel Burkhoff
Physical training alters the pathogenesis of pacing-induced heart failure through endothelium-mediated mechanisms in awake dogs.
Circulation 1997;96(8):2683-92.
1997: Rochelle L Goldsmith; J Thomas Bigger; Daniel M Bloomfield; Henry Krum; Richard C Steinman; Jonathan D Sackner-Bernstein; Milton Packer
Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure.
The American journal of cardiology 1997;80(8):1101-4.
1997: Jay N Cohn; Michael B Fowler; Michael R Bristow; WS Colucci; Edward M Gilbert; V Kinhal; Steven K Krueger; T Lejemtel; K A Narahara; Milton Packer; ST Young; Terry L Holcslaw; Mary Ann Lukas
Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group.
Journal of cardiac failure 1997;3(3):173-9.
1997: Kirkwood F Adams; Mihai Gheorghiade; Barry F Uretsky; J B Young; S Ahmed; L Tomasko; Milton Packer
Patients with mild heart failure worsen during withdrawal from digoxin therapy.
Journal of the American College of Cardiology 1997;30(1):42-8.
1997: Koji Todaka; Jack Wang; Geng-Hua Yi; M Knecht; R Stennett; Milton Packer; Daniel Burkhoff
Impact of exercise training on ventricular properties in a canine model of congestive heart failure.
The American journal of physiology 1997;272(3 Pt 2):H1382-90.
1997: Milton Packer
End of the oldest controversy in medicine. Are we ready to conclude the debate on digitalis?
The New England journal of medicine 1997;336(8):575-6.
1997: M Knecht; Daniel Burkhoff; Geng-Hua Yi; Sulli Popilskis; Shunichi Homma; Milton Packer; Jack Wang
Coronary endothelial dysfunction precedes heart failure and reduction of coronary reserve in awake dogs.
Journal of molecular and cellular cardiology 1997;29(1):217-27.
1997: Koji Todaka; DW Leibowitz; Shunichi Homma; Peter E Fisher; CM Derosa; R Stennett; Milton Packer; Daniel Burkhoff
Characterizing ventricular mechanics and energetics following repeated coronary microembolization.
The American journal of physiology 1997;272(1 Pt 2):H186-94.
1996: L S Marcus; D Hart; Milton Packer; M Yushak; N Medina; Robert S Danziger; D F Heitjan; Stuart D Katz
Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial.
Circulation 1996;94(12):3184-9.
1996: Wilson S Colucci; Milton Packer; Michael R Bristow; Edward M Gilbert; Jay N Cohn; M B Fowler; S K Krueger; Ray E Hershberger; B F Uretsky; J A Bowers; J D Sackner-Bernstein; S T Young; T L Holcslaw; M A Lukas
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.
Circulation 1996;94(11):2800-6.
1996: Milton Packer; Wilson S Colucci; J D Sackner-Bernstein; C S Liang; D A Goldscher; I Freeman; Marrick L Kukin; V Kinhal; J E Udelson; M Klapholz; Stephen S Gottlieb; D Pearle; robert cody; J J Gregory; N E Kantrowitz; Thierry H LeJemtel; S T Young; M A Lukas; N H Shusterman
Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.
Circulation 1996;94(11):2793-9.
1996: Milton Packer
Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?
Journal of the American College of Cardiology 1996;28(5):1323-7.
1996: Milton Packer; Christopher M O'Connor; Jalal K Ghali; Milton L Pressler; P E Carson; R N Belkin; Alan B Miller; G W Neuberg; D Frid; J H Wertheimer; Anne B Cropp; D L DeMets
Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.
The New England journal of medicine 1996;335(15):1107-14.
1996: Koji Todaka; Jack Wang; Geng-Hua Yi; R Stennett; M Knecht; Milton Packer; Daniel Burkhoff
Effects of levosimendan on myocardial contractility and oxygen consumption.
The Journal of pharmacology and experimental therapeutics 1996;279(1):120-7.
1996: Barrie Massie; NB Shah; Bertram Pitt; Milton Packer
Importance of assessing changes in ventricular response to atrial fibrillation during evaluation of new heart failure therapies: experience from trials of flosequinan.
American heart journal 1996;132(1 Pt 1):130-6.
1996: Milton Packer; Michael R Bristow; J N Cohn; Wilson S Colucci; M B Fowler; E M Gilbert; N H Shusterman
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
The New England journal of medicine 1996;334(21):1349-55.
1996: Milton Packer
New concepts in the pathophysiology of heart failure: beneficial and deleterious interaction of endogenous haemodynamic and neurohormonal mechanisms.
Journal of internal medicine 1996;239(4):327-33.
1996: Milton Packer
Beta-blockade in the management of chronic heart failure. Another step in the conceptual evolution of a neurohormonal model of the disease.
European heart journal 1996;17 Suppl B():21-3.
1996: Henry Krum; Anguo Gu; M Wilshire-Clement; J Sackner-Bernstein; Rochelle L Goldsmith; N Medina; M Yushak; Myron Miller; Milton Packer
Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure.
American heart journal 1996;131(2):337-41.
1995: Milton Packer
Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure?
Circulation 1995;92(6):1379-82.
1995: Milton Packer
Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure.
European heart journal 1995;16 Suppl F():4-6.
1995: Henry Krum; Rochelle L Goldsmith; M Wilshire-Clement; Myron Miller; Milton Packer
Role of endothelin in the exercise intolerance of chronic heart failure.
The American journal of cardiology 1995;75(17):1282-3.
1995: HR Levin; Mehmet C Oz; Jonathan M Chen; Milton Packer; Eric A Rose; Daniel Burkhoff
Reversal of chronic ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical unloading.
Circulation 1995;91(11):2717-20.
1995: Henry Krum; J Thomas Bigger; Rochelle L Goldsmith; Milton Packer
Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure.
Journal of the American College of Cardiology 1995;25(2):289-94.
1995: E M Gilbert; Milton Packer
The use of placebo controls.
The New England journal of medicine 1995;332(1):61; author reply 62.
1995: Milton Packer
A novel approach to the development of positive inotropic agents for chronic heart failure.
Journal of cardiovascular pharmacology 1995;26 Suppl 1():S52-6.
1995: E M Horn; Marrick L Kukin; G W Neuberg; Rochelle L Goldsmith; M McCarty; M Gratch; N Medina; M Yushak; Milton Packer; John P Bilezikian
Lymphocyte G proteins reflect response to treatment in congestive heart failure.
American heart journal 1995;129(1):98-106.
1994: HR Levin; Jonathan M Chen; Mehmet C Oz; Katharine A Catanese; Henry Krum; Rochelle L Goldsmith; Milton Packer; Eric A Rose
Potential of left ventricular assist devices as outpatient therapy while awaiting transplantation.
The Annals of thoracic surgery 1994;58(5):1515-20.
1994: J D Rutherford; Marc A Pfeffer; Lemuel A Moyé; B R Davis; Greg C Flaker; P R Kowey; Gervasio A Lamas; Hugh S Miller; Milton Packer; Jean-Lucien Rouleau
Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators.
Circulation 1994;90(4):1731-8.
1994: Jean-Lucien Rouleau; Milton Packer; Lemuel A Moyé; J de Champlain; D Bichet; M Klein; J R Rouleau; Bruce Sussex; J M Arnold; F Sestier
Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril.
Journal of the American College of Cardiology 1994;24(3):583-91.
1994: C Hall; Jean-Lucien Rouleau; L Moyè; J de Champlain; D Bichet; M Klein; Bruce Sussex; Milton Packer; J Rouleau; M O Arnold
N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction.
Circulation 1994;89(5):1934-42.
1993: Stephen S Gottlieb; Marrick L Kukin; J Penn; Michael L Fisher; M Cines; N Medina; M Yushak; M Taylor; Milton Packer
Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors.
Journal of the American College of Cardiology 1993;22(4):963-7.
1993: Milton Packer
The development of positive inotropic agents for chronic heart failure: how have we gone astray?
Journal of the American College of Cardiology 1993;22(4 Suppl A):119A-126A.
1993: R Garg; Milton Packer; Bertram Pitt; S Yusuf
Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine.
Journal of the American College of Cardiology 1993;22(4 Suppl A):3A-5A.
1993: R J Lipicky; Milton Packer
Role of surrogate end points in the evaluation of drugs for heart failure.
Journal of the American College of Cardiology 1993;22(4 Suppl A):179A-184A.
1993: Barrie Massie; Martin Berk; S C Brozena; U Elkayam; J F Plehn; Marrick L Kukin; Milton Packer; B E Murphy; G W Neuberg; Richard M Steingart
Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).
Circulation 1993;88(2):492-501.
1993: Jean-Lucien Rouleau; J de Champlain; M Klein; D Bichet; Lemuel A Moyé; Milton Packer; G R Dagenais; Bruce Sussex; J M Arnold; F Sestier
Activation of neurohumoral systems in postinfarction left ventricular dysfunction.
Journal of the American College of Cardiology 1993;22(2):390-8.
1993: Milton Packer
The search for the ideal positive inotropic agent.
The New England journal of medicine 1993;329(3):201-2.
1993: Milton Packer; K A Narahara; U Elkayam; J M Sullivan; D L Pearle; Barrie Massie; M A Creager
Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study.
Journal of the American College of Cardiology 1993;22(1):65-72.
1993: Milton Packer; Mihai Gheorghiade; J B Young; P J Costantini; Kirkwood F Adams; robert cody; L K Smith; L Van Voorhees; L A Gourley; M K Jolly
Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study.
The New England journal of medicine 1993;329(1):1-7.
1993: S K Gupta; G Richard Granneman; Milton Packer; R S Boger
Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a renin inhibitor). II: A dose-ranging study in patients with congestive heart failure.
Journal of cardiovascular pharmacology 1993;21(5):834-40.
1993: Milton Packer
How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease.
The American journal of cardiology 1993;71(9):3C-11C.
1993: Eric J Eichhorn; P K Tandon; R DiBianco; G C Timmis; P E Fenster; J Shannon; Milton Packer
Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study.
Journal of the American College of Cardiology 1993;21(3):634-40.
1993: Milton Packer
Calcium antagonists for congestive heart failure: evolving concepts in bridge building.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1993;7(1):95-6.
1992: Milton Packer
Treatment of chronic heart failure.
Lancet 1992;340(8811):92-5.
1992: Milton Packer
Pathophysiology of chronic heart failure.
Lancet 1992;340(8811):88-92.
1992: Milton Packer
The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure.
Journal of the American College of Cardiology 1992;20(1):248-54.
1992: Milton Packer
Long-term strategies in the management of heart failure: looking beyond ventricular function and symptoms.
The American journal of cardiology 1992;69(18):150G-154G.
1992: Bertram Pitt; J N Cohn; G S Francis; John B Kostis; Milton Packer; M A Pfeffer; K Swedberg; S Yusuf
The effect of treatment on survival in congestive heart failure.
Clinical cardiology 1992;15(5):323-9.
1992: Milton Packer
Lack of relation between ventricular arrhythmias and sudden death in patients with chronic heart failure.
Circulation 1992;85(1 Suppl):I50-6.
1991: Milton Packer; J R Carver; R J Rodeheffer; R J Ivanhoe; R DiBianco; S M Zeldis; Grady H. Hendrix; William J Bommer; U Elkayam; Marrick L Kukin
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
The New England journal of medicine 1991;325(21):1468-75.
1991: Jean-Lucien Rouleau; Lemuel A Moyé; J de Champlain; M Klein; D Bichet; Milton Packer; G Dagenais; Bruce Sussex; J M Arnold; F Sestier
Activation of neurohumoral systems following acute myocardial infarction.
The American journal of cardiology 1991;68(14):80D-86D.
1991: Richard M Steingart; Milton Packer; P Hamm; M E Coglianese; B Gersh; E M Geltman; J Sollano; S Katz; Lemuel A Moyé; L L Basta
Sex differences in the management of coronary artery disease. Survival and Ventricular Enlargement Investigators.
The New England journal of medicine 1991;325(4):226-30.
1991: Milton Packer; M L Kukin
Management of patients with heart failure and angina: do coexistent diseases alter the response to cardiovascular drugs?
Journal of the American College of Cardiology 1991;17(3):740-2.
1991: H L Haber; J A Leavy; P D Kessler; Marrick L Kukin; Stephen S Gottlieb; Milton Packer
The erythrocyte sedimentation rate in congestive heart failure.
The New England journal of medicine 1991;324(6):353-8.
1991: G W Neuberg; Marrick L Kukin; J Penn; N Medina; M Yushak; Milton Packer
Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure.
The American journal of cardiology 1991;67(1):63-6.
1990: Milton Packer
The placebo effect in heart failure.
American heart journal 1990;120(6 Pt 2):1579-82.
1990: Milton Packer
Calcium channel blockers in chronic heart failure. The risks of "physiologically rational" therapy.
Circulation 1990;82(6):2254-7.
1990: Stephen S Gottlieb; L Baruch; Marrick L Kukin; Jonine L Bernstein; Michael L Fisher; Milton Packer
Prognostic importance of the serum magnesium concentration in patients with congestive heart failure.
Journal of the American College of Cardiology 1990;16(4):827-31.
1990: Milton Packer
Are nitrates effective in the treatment of chronic heart failure? Antagonist's viewpoint.
The American journal of cardiology 1990;66(4):458-61.
1990: Milton Packer
Role of the sympathetic nervous system in chronic heart failure. A historical and philosophical perspective.
Circulation 1990;82(2 Suppl):I1-6.
1990: Milton Packer
Pathophysiological mechanisms underlying the effects of beta-adrenergic agonists and antagonists on functional capacity and survival in chronic heart failure.
Circulation 1990;82(2 Suppl):I77-88.
1990: Beth Levine; J Kalman; L Mayer; H M Fillit; Milton Packer
Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.
The New England journal of medicine 1990;323(4):236-41.
1990: Milton Packer
Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition.
European heart journal 1990;11 Suppl D():44-52.
1990: Milton Packer
Diastolic function as a target of therapeutic interventions in chronic heart failure.
European heart journal 1990;11 Suppl C():35-40.
1990: Milton Packer
Potential role of potassium as a determinant of morbidity and mortality in patients with systemic hypertension and congestive heart failure.
The American journal of cardiology 1990;65(10):45E-51E; discussion 52E.
1990: Milton Packer
Hormone-electrolyte interactions in congestive heart failure: lessons from a 4,000-year-old Sumerian tablet.
The American journal of cardiology 1990;65(10):1E-3E; discussion 22E-23E.
1990: Stephen S Gottlieb; Marrick L Kukin; N Medina; M Yushak; Milton Packer
Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure.
Circulation 1990;81(3):860-4.
1990: Milton Packer
Abnormalities of diastolic function as a potential cause of exercise intolerance in chronic heart failure.
Circulation 1990;81(2 Suppl):III78-86.
1989: Milton Packer
Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure.
Circulation 1989;80(6 Suppl):IV59-67.
1989: Milton Packer
Second generation calcium channel blockers in the treatment of chronic heart failure: are they any better than their predecessors?
Journal of the American College of Cardiology 1989;14(5):1339-42.
1989: Stephen S Gottlieb; Milton Packer
Deleterious hemodynamic effects of lidocaine in severe congestive heart failure.
American heart journal 1989;118(3):611-2.
1989: A Gradman; P Deedwania; robert cody; Barrie Massie; Milton Packer; Bertram Pitt; S Goldstein
Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group.
Journal of the American College of Cardiology 1989;14(3):564-70; discussion 571-2.
1989: Milton Packer; Marrick L Kukin; G W Neuberg; David J Pinsky; J Penn; M H Abittan
The current status of angiotensin converting enzyme inhibitors in the management of patients with chronic heart failure.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1989;7(5):S33-6.
1989: Milton Packer
Is it ethical to administer vasodilator drugs to patients with primary pulmonary hypertension?
Chest 1989;95(6):1173-5.
1989: Stephen S Gottlieb; Marrick L Kukin; D Ahern; Milton Packer
Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure.
Journal of the American College of Cardiology 1989;13(7):1534-9.
1989: Milton Packer
The clinical significance of nitrate tolerance in patients with chronic heart failure.
European heart journal 1989;10 Suppl A():20-5.
1989: Stephen S Gottlieb; Marrick L Kukin; M Yushak; N Medina; Milton Packer
Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure.
Annals of internal medicine 1989;110(7):505-9.
1989: Milton Packer
Drug therapy. Combined beta-adrenergic and calcium-entry blockade in angina pectoris.
The New England journal of medicine 1989;320(11):709-18.
1989: Milton Packer
Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure.
The American journal of cardiology 1989;63(2):41A-45A.
1989: Milton Packer
Identification of risk factors predisposing to the development of functional renal insufficiency during treatment with converting-enzyme inhibitors in chronic heart failure.
Cardiology 1989;76 Suppl 2():50-5.
1989: Milton Packer
Therapeutic options in the management of chronic heart failure. Is there a drug of first choice?
Circulation 1989;79(1):198-204.
1989: Milton Packer
Does digitalis work in chronic heart failure? The end of a 200-year-old controversy.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1989;2(6):743-6.
1989: Milton Packer
Is activation of the sympathetic nervous system beneficial or detrimental to the patient with chronic heart failure? Lessons learned from clinical trials with beta-adrenergic agonists and antagonists.
Journal of cardiovascular pharmacology 1989;14 Suppl 5():S38-43.
1988: Milton Packer
Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope.
Journal of the American College of Cardiology 1988;12(5):1299-317.
1988: Milton Packer
Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? II. Protagonist's viewpoint.
Journal of the American College of Cardiology 1988;12(2):562-6.
1988: Milton Packer
Symposium on therapeutic challenges in the management of congestive heart failure. Part I.
Journal of the American College of Cardiology 1988;12(1):262-4.
1988: Milton Packer
Clinical trials in congestive heart failure: why do studies report conflicting results?
Annals of internal medicine 1988;109(1):3-5.
1988: P D Kessler; Milton Packer; N Medina; M Yushak
Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure.
Journal of cardiovascular pharmacology 1988;12(1):6-11.
1988: Milton Packer
Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure.
Circulation 1988;77(6 Pt 2):I64-73.
1988: Milton Packer
Effect of vasodilator and inotropic drugs on clinical symptoms and long-term survival in chronic congestive heart failure.
European heart journal 1988;9 Suppl H():105-8.
1988: Milton Packer
Neurohormonal interactions and adaptations in congestive heart failure.
Circulation 1988;77(4):721-30.
1988: Milton Packer
Modulation of functional capacity and survival in congestive heart failure. Effects of activation of the sympathetic nervous system.
Postgraduate medicine 1988;Spec No():96-103.
1987: Milton Packer; W H Lee; N Medina; M Yushak; Jonine L Bernstein; P D Kessler
Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction.
Journal of the American College of Cardiology 1987;10(6):1303-11.
1987: Milton Packer; W H Lee; P D Kessler; N Medina; M Yushak; Stephen S Gottlieb
Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure.
Journal of the American College of Cardiology 1987;10(4):837-44.
1987: Milton Packer; W H Lee; P D Kessler; Stephen S Gottlieb; N Medina; M Yushak
Prevention and reversal of nitrate tolerance in patients with congestive heart failure.
The New England journal of medicine 1987;317(13):799-804.
1987: Milton Packer
Adaptive and maladaptive actions of angiotensin II in patients with severe congestive heart failure.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1987;10(1 Suppl 1):66-73.
1987: Milton Packer
Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition.
The American journal of cardiology 1987;60(1):179-84.
1987: Milton Packer
Do vasodilators prolong life in heart failure?
The New England journal of medicine 1987;316(23):1471-3.
1987: Milton Packer; P D Kessler; W H Lee
Calcium-channel blockade in the management of severe chronic congestive heart failure: a bridge too far.
Circulation 1987;75(6 Pt 2):V56-64.
1987: Milton Packer; W H Lee; N Medina; M Yushak; P D Kessler; Stephen S Gottlieb
Influence of diabetes mellitus on changes in left ventricular performance and renal function produced by converting enzyme inhibition in patients with severe chronic heart failure.
The American journal of medicine 1987;82(6):1119-26.
1987: Milton Packer
Prolonging life in patients with congestive heart failure: the next frontier. Introduction.
Circulation 1987;75(5 Pt 2):IV1-3.
1987: Milton Packer; C V Leier
Survival in congestive heart failure during treatment with drugs with positive inotropic actions.
Circulation 1987;75(5 Pt 2):IV55-63.
1987: Milton Packer; W H Lee; P D Kessler; Stephen S Gottlieb; Jonine L Bernstein; Marrick L Kukin
Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure.
Circulation 1987;75(5 Pt 2):IV80-92.
1987: Milton Packer; Stephen S Gottlieb; M A Blum
Immediate and long-term pathophysiologic mechanisms underlying the genesis of sudden cardiac death in patients with congestive heart failure.
The American journal of medicine 1987;82(3A):4-10.
1987: Milton Packer; W H Lee; N Medina; M Yushak; P D Kessler
Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure.
Annals of internal medicine 1987;106(3):346-54.
1987: Milton Packer
How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind men.
Journal of the American College of Cardiology 1987;9(2):433-8.
1987: P D Kessler; Milton Packer
Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failure.
American heart journal 1987;113(1):137-43.
1987: Milton Packer
Converting-enzyme inhibition in the management of severe chronic congestive heart failure: physiologic concepts.
Journal of cardiovascular pharmacology 1987;10 Suppl 7():S83-7.
1987: Milton Packer; W H Lee; P D Kessler; Stephen S Gottlieb
Can we expect vasodilator therapy to prolong life in patients with congestive heart failure?
Journal of cardiovascular pharmacology 1987;9 Suppl 2():S73-5.
1986: Milton Packer; W H Lee; M Yushak; N Medina
Comparison of captopril and enalapril in patients with severe chronic heart failure.
The New England journal of medicine 1986;315(14):847-53.
1986: Milton Packer; W H Lee; P D Kessler
Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system.
Circulation 1986;74(4):766-74.
1986: Milton Packer; N Medina; M Yushak
Comparative hemodynamic and clinical effects of long-term treatment with prazosin and captopril for severe chronic congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy.
The American journal of cardiology 1986;57(15):1323-7.
1986: Milton Packer; Stephen S Gottlieb; P D Kessler
Hormone-electrolyte interactions in the pathogenesis of lethal cardiac arrhythmias in patients with congestive heart failure. Basis of a new physiologic approach to control of arrhythmia.
The American journal of medicine 1986;80(4A):23-9.
1986: Milton Packer; W H Lee; N Medina; M Yushak
Systemic vasoconstrictor effects of oxygen administration in obliterative pulmonary vascular disorders.
The American journal of cardiology 1986;57(10):853-8.
1986: Milton Packer; N Medina; M Yushak
Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure.
Journal of the American College of Cardiology 1986;7(3):671-80.
1986: Milton Packer; N Medina; M Yushak; W H Lee
Hemodynamic factors limiting the response to transdermal nitroglycerin in severe chronic congestive heart failure.
The American journal of cardiology 1986;57(4):260-7.
1986: Milton Packer; W H Lee
Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure.
The American journal of cardiology 1986;57(4):347-8.
1986: W H Lee; Milton Packer
Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure.
Circulation 1986;73(2):257-67.
1986: Milton Packer; W H Lee; N Medina; M Yushak
Influence of renal function on the hemodynamic and clinical responses to long-term captopril therapy in severe chronic heart failure.
Annals of internal medicine 1986;104(2):147-54.
1986: Milton Packer
The role of vasodilator therapy in the treatment of severe chronic heart failure.
Drugs 1986;32 Suppl 5():13-26.
1986: Milton Packer; N Medina; M Yushak
Comparative immediate hemodynamic and hormonal effects of amrinone and captopril in patients with severe chronic heart failure.
The American journal of the medical sciences 1986;291(1):8-15.
1986: Milton Packer; P D Kessler; Stephen S Gottlieb
Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management.
Postgraduate medical journal 1986;62 Suppl 1():179-82.
1985: Milton Packer
Does pulmonary vasoconstriction play an important role in patients with primary pulmonary hypertension? A skeptic's view of vasodilator therapy.
Chest 1985;88(4 Suppl):265S-268S.
1985: Milton Packer
Sudden unexpected death in patients with congestive heart failure: a second frontier.
Circulation 1985;72(4):681-5.
1985: Milton Packer; N Medina; M Yushak; W H Lee
Usefulness of plasma renin activity in predicting haemodynamic and clinical responses and survival during long term converting enzyme inhibition in severe chronic heart failure. Experience in 100 consecutive patients.
British heart journal 1985;54(3):298-304.
1985: Milton Packer; W H Lee; N Medina; M Yushak
Hemodynamic and clinical significance of the pulmonary vascular response to long-term captopril therapy in patients with severe chronic heart failure.
Journal of the American College of Cardiology 1985;6(3):635-45.
1985: Milton Packer
Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards.
Annals of internal medicine 1985;103(2):258-70.
1985: Milton Packer
Mechanisms of nitrate action in patients with severe left ventricular failure: conceptual problems with the theory of venosequestration.
American heart journal 1985;110(1 Pt 2):259-64.
1985: Milton Packer; N Medina; M Yushak; W H Lee
Comparative effects of captopril and isosorbide dinitrate on pulmonary arteriolar resistance and right ventricular function in patients with severe left ventricular failure: results of a randomized crossover study.
American heart journal 1985;109(6):1293-9.
1985: Barrie Massie; M Bourassa; R DiBianco; M Hess; M Konstam; M Likoff; Milton Packer
Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial.
Circulation 1985;71(5):963-71.
1985: Milton Packer; N Medina; M Yushak
Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure.
Circulation 1985;71(4):761-6.
1985: Milton Packer
Converting-enzyme inhibition for severe chronic heart failure: views from a skeptic.
International journal of cardiology 1985;7(2):111-20.
1985: Milton Packer
Therapeutic application of calcium-channel antagonists for pulmonary hypertension.
The American journal of cardiology 1985;55(3):196B-201B.
1984: Milton Packer; N Medina; M Yushak
Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure.
Circulation 1984;70(6):1038-47.
1984: Milton Packer; N Medina; M Yushak
Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure.
The American journal of cardiology 1984;54(8):1025-9.
1984: Milton Packer; N Medina; M Yushak
Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease.
Journal of the American College of Cardiology 1984;4(5):890-901.
1984: Milton Packer; N Medina; M Yushak
Efficacy of captopril in low-renin congestive heart failure: importance of sustained reactive hyperreninemia in distinguishing responders from nonresponders.
The American journal of cardiology 1984;54(7):771-7.
1984: Milton Packer; N Medina; M Yushak; I Wiener
Detrimental effects of verapamil in patients with primary pulmonary hypertension.
British heart journal 1984;52(1):106-11.
1984: Milton Packer
Conceptual dilemmas in the classification of vasodilator drugs for severe chronic heart failure. Advocacy of a pragmatic approach to the selection of a therapeutic agent.
The American journal of medicine 1984;76(6A):3-13.
1984: Milton Packer; N Medina; M Yushak
Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition.
Annals of internal medicine 1984;100(6):782-9.
1984: M E Goldman; Milton Packer; S F Horowitz; J Meller; R E Patterson; M Kukin; L E Teichholz; R Gorlin
Relation between exercise-induced changes in ejection fraction and systolic loading conditions at rest in aortic regurgitation.
Journal of the American College of Cardiology 1984;3(4):924-9.
1984: Milton Packer; N Medina; M Yushak
Relation between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure.
Journal of the American College of Cardiology 1984;3(4):1035-43.
1984: V J Dzau; Milton Packer; L S Lilly; S L Swartz; N K Hollenberg; G H Williams
Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia.
The New England journal of medicine 1984;310(6):347-52.
1983: Milton Packer
Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism.
Journal of the American College of Cardiology 1983;2(5):841-52.
1983: Milton Packer; N Medina; M Yushak; J Meller
Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure.
Circulation 1983;68(4):803-12.
1983: Barrie Massie; Milton Packer; J T Hanlon; D T Combs
Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failure.
Journal of the American College of Cardiology 1983;2(2):338-44.
1983: Milton Packer
New perspectives on therapeutic application of nitrates as vasodilator agents for severe chronic heart failure.
The American journal of medicine 1983;74(6B):61-72.
1983: M Cohen; Milton Packer; R Gorlin
Indications for left ventricular aneurysmectomy.
Circulation 1983;67(4):717-22.
1983: Milton Packer; J Meller; N Medina; M Yushak
Quantitative differences in the hemodynamic effects of captopril and nitroprusside in severe chronic heart failure.
The American journal of cardiology 1983;51(1):183-8.
1982: Milton Packer; N Medina; M Yushak
Contrasting hemodynamic responses in severe heart failure: comparison of captopril and other vasodilator drugs.
American heart journal 1982;104(5 Pt 2):1215-23.
1982: Milton Packer; M B Leon; R O Bonow; J Kieval; D R Rosing; V B Subramanian
Hemodynamic and clinical effects of combined verapamil and propranolol therapy in angina pectoris.
The American journal of cardiology 1982;50(4):903-12.
1982: B N Singh; C Y Chew; M A Josephson; Milton Packer
Part I: pharmacologic and hemodynamic actions and interactions. Pharmacologic and hemodynamic mechanisms underlying the antianginal actions of verapamil.
The American journal of cardiology 1982;50(4):886-93.
1982: Milton Packer; W H Frishman
Verapamil therapy for stable and unstable angina pectoris: calcium channel antagonists in perspective.
The American journal of cardiology 1982;50(4):881-5.
1982: Milton Packer; R Gorlin; J Meller; N Medina
Central hemodynamic effects of dipyridamole in severe heart failure: comparison with hydralazine.
Clinical pharmacology and therapeutics 1982;32(1):54-61.
1982: Milton Packer
Selection of vasodilator drugs for patients with severe chronic heart failure: an approach based on a new classification.
Drugs 1982;24(1):64-74.
1982: Milton Packer; B Greenberg; Barrie Massie; H Dash
Deleterious effects of hydralazine in patients with pulmonary hypertension.
The New England journal of medicine 1982;306(22):1326-31.
1982: Milton Packer; J Meller; N Medina; M Yushak; H Smith; J Holt; J Guererro; G D Todd; R G McAllister; R Gorlin
Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man.
Circulation 1982;65(4):660-8.
1982: Milton Packer; J Meller; N Medina; M Yushak; R Gorlin
Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure.
The New England journal of medicine 1982;306(2):57-62.
1982: Milton Packer; T H Le Jemtel
Physiologic and pharmacologic determinants of vasodilator response: a conceptual framework for rational drug therapy for chronic heart failure.
Progress in cardiovascular diseases 1982;24(4):275-92.
1981: Milton Packer; J Meller; N Medina; M Yushak; R Gorlin
Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure. Clinical and hemodynamic evaluation of 52 consecutive patients with ischemic cardiomyopathy.
The American journal of cardiology 1981;48(5):939-46.
1981: Milton Packer; J Meller; N Medina; M Yushak; R Gorlin
Determinants of drug response in severe chronic heart failure. 1. Activation of vasoconstrictor forces during vasodilator therapy.
Circulation 1981;64(3):506-14.
1981: Milton Packer; J Meller; N Medina; M Yushak
Sustained effectiveness of minoxidil in heart failure after development of tolerance to other vasodilator drugs.
The American journal of cardiology 1981;48(2):375-9.
1981: J Urquhart; R E Patterson; Milton Packer; S J Goldsmith; S F Horowitz; R Litwak; R Gorlin
Quantification of valve regurgitation by radionuclide angiography before and after valve replacement surgery.
The American journal of cardiology 1981;47(2):287-91.
1980: Milton Packer; J Meller; N Medina; R Gorlin; M V Herman
Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure.
The New England journal of medicine 1980;303(5):250-5.
1980: Milton Packer; J Meller; N Medina; R Gorlin; M V Herman
Hemodynamic evaluation of hydralazine dosage in refractory heart failure.
Clinical pharmacology and therapeutics 1980;27(3):337-46.
1980: Milton Packer; J Meller; N Medina; R Gorlin; M V Herman
Dose requirements of hydralazine in patients with severe chronic congestive heart failure.
The American journal of cardiology 1980;45(3):655-60.
1980: Milton Packer
Is there a drug of choice for vasodilator therapy in patients with refractory heart failure?
Chest 1980;77(1):7-9.
1979: Milton Packer; J Meller; N Medina; R Gorlin; M V Herman
Rebound hemodynamic events after the abrupt withdrawal of nitroprusside in patients with severe chronic heart failure.
The New England journal of medicine 1979;301(22):1193-7.
1979: Milton Packer; J Meller; R Gorlin; M V Herman
Differences in hemodynamic effects of nitroprusside and prazosin in severe chronic congestive heart failure: evidence for a direct negative chronotropic effect of prazosin.
The American journal of cardiology 1979;44(2):310-7.
1979: Milton Packer; J Meller; R Gorlin; M V Herman
Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure.
Circulation 1979;59(3):531-9.
1978: Milton Packer; J Meller
Oral vasodilator therapy for chronic heart failure: a plea for caution.
The American journal of cardiology 1978;42(4):686-9.